Can-Fite BioPharma American Depositary Shares
CANF
6 hedge funds and large institutions have $225K invested in Can-Fite BioPharma American Depositary Shares in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
20% more funds holding
Funds holding: 5 → 6 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
12% less capital invested
Capital invested by funds: $254K → $225K (-$29.3K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$87K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$101K |
| 2 |
Morgan Stanley
New York
|
-$54.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$48K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $107K | +$87K | +162 | New |
|
|
2
Morgan Stanley
New York
| $100K | -$54.2K | -101 | -40% |
|
|
3
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $13K | +$10.7K | +20 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $2K | +$2.15K | +4 | New |
|
|
FDCDDQ
5
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $1.76K | – | – | – |
|
|
AF
6
Advisornet Financial
Minnetonka,
Minnesota
| $1K | – | – | – |
|
|
7
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$101K | -246 | Closed |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$48K | -116 | Closed |
|
CANF Hedge Fund Activity: Q4 2019 in Review
6 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q4 2019, worth a combined $225K — down 12% from $254K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CANF positions and 2 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $87K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $101K sold.
- 6 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q4 2019, up from 5 in Q3 2019.
- Funds reported $225K of Can-Fite BioPharma American Depositary Shares stock for Q4 2019, down 12% quarter-over-quarter.
- 3 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q4 2019 and 2 closed out, a net change of +1 holder.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q4 2019 was Renaissance Technologies, an estimated $87K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q4 2019 was Susquehanna International Group, an estimated $101K sold.
Based on aggregated 13F filings for Q4 2019.